ACHIEVE LIFE SCIENCES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | — | $22.8M | $15.8M | $30.1M | $24.0M |
| Interest expense | $819,000 | $2.2M | $2.9M | $1.8M | — |
| Pretax income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M |
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M |
| Balance Sheet | |||||
| Cash and equivalents | $20.9M | $12.8M | $15.5M | $24.8M | $43.0M |
| Current assets | $39.9M | $36.5M | $17.0M | $27.3M | $44.6M |
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M |
| Current liabilities | $9.1M | $6.7M | $20.8M | $21.6M | $4.5M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M |
| Stockholders' equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M |
| Depreciation and amortization | $228,000 | $229,000 | $228,000 | $236,000 | $27,000 |
| Stock-based compensation | $8.8M | $5.3M | $3.4M | $3.3M | $2.2M |
| Capital expenditure | $3,000 | — | $21,000 | — | — |
| Free cash flow | -$49.5M | — | -$24.5M | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 102.7M · Free float 58.2%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.